- Home
- LUCD vs ITRM Comparison
LUCD vs ITRM Comparison
Compare LUCD & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- ITRM
- Stock Information
- Founded
- LUCD 2018
- ITRM 2015
- Country
- LUCD United States
- ITRM Ireland
- Employees
- LUCD N/A
- ITRM N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- ITRM Health Care
- Exchange
- LUCD Nasdaq
- ITRM Nasdaq
- Market Cap
- LUCD 51.6M
- ITRM 47.7M
- IPO Year
- LUCD 2021
- ITRM 2018
- Fundamental
- Price
- LUCD $1.22
- ITRM $1.34
- Analyst Decision
- LUCD Strong Buy
- ITRM Strong Buy
- Analyst Count
- LUCD 4
- ITRM 1
- Target Price
- LUCD $3.63
- ITRM $5.00
- AVG Volume (30 Days)
- LUCD 986.1K
- ITRM 357.1K
- Earning Date
- LUCD 03-24-2025
- ITRM 02-07-2025
- Dividend Yield
- LUCD N/A
- ITRM N/A
- EPS Growth
- LUCD N/A
- ITRM N/A
- EPS
- LUCD N/A
- ITRM N/A
- Revenue
- LUCD $4,189,000.00
- ITRM N/A
- Revenue This Year
- LUCD $91.72
- ITRM N/A
- Revenue Next Year
- LUCD $139.38
- ITRM $160.88
- P/E Ratio
- LUCD N/A
- ITRM N/A
- Revenue Growth
- LUCD 179.27
- ITRM N/A
- 52 Week Low
- LUCD $0.63
- ITRM $0.81
- 52 Week High
- LUCD $1.63
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- LUCD 46.35
- ITRM 40.11
- Support Level
- LUCD $1.27
- ITRM $1.25
- Resistance Level
- LUCD $1.47
- ITRM $1.46
- Average True Range (ATR)
- LUCD 0.16
- ITRM 0.09
- MACD
- LUCD -0.04
- ITRM 0.00
- Stochastic Oscillator
- LUCD 15.59
- ITRM 31.03
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.